Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc.
Your view on BCLI
Overview
What the company does, where it operates, and who runs it.
About Brainstorm Cell Therapeutics Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Chaim Lebovits
- Headquarters
- 1325 Avenue of Americas, New York City, NY, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Chaim Lebovits
- Headquarters
- 1325 Avenue of Americas, New York City, NY, US
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases.
The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.
It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn.
The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Brainstorm Cell Therapeutics Inc., and the rating behind it. BCLI last traded at $0.62; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Brainstorm Cell Therapeutics Inc.. Starting points for Brainstorm Cell Therapeutics Inc.: EPS -$0.95, beta 0.53 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Brainstorm Cell Therapeutics Inc.. Brainstorm Cell Therapeutics Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Brainstorm Cell Therapeutics Inc.. Trailing twelve-month EPS for Brainstorm Cell Therapeutics Inc. stands at -$0.95. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Brainstorm Cell Therapeutics Inc.. Brainstorm Cell Therapeutics Inc. has reported as a listed company since 2003. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Brainstorm Cell Therapeutics Inc. valued side by side against its closest peers. Brainstorm Cell Therapeutics Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Brainstorm Cell Therapeutics Inc., and how their positions are changing. At a $6.8M market value, institutional positions materially move Brainstorm Cell Therapeutics Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Brainstorm Cell Therapeutics Inc. executives and directors. Shares of Brainstorm Cell Therapeutics Inc. have traded between $0.52 and $2.50 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Brainstorm Cell Therapeutics Inc.. Brainstorm Cell Therapeutics Inc. is a $6.8M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Brainstorm Cell Therapeutics Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Brainstorm Cell Therapeutics Inc.. Coverage tracks Brainstorm Cell Therapeutics Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.